KRAS Kickers (@KRASKickers) header
KRAS Kickers (@KRASKickers) profile picture

#KRAS 🎯cancer patient group for reliable Knowledge Research Advocacy & Survivorship. Survival of the strategic. #KickCancersKRAS - 🚫 #KRASholes

International, ALL RAS cancers
Joined February 2020
Photo by KRAS Kickers (@KRASKickers)Photo by KRAS Kickers (@KRASKickers)Photo by KRAS Kickers (@KRASKickers)Photo by KRAS Kickers (@KRASKickers)Photo by KRAS Kickers (@KRASKickers)Photo by KRAS Kickers (@KRASKickers)Photo by KRAS Kickers (@KRASKickers)Photo by KRAS Kickers (@KRASKickers)Photo by KRAS Kickers (@KRASKickers)Photo by KRAS Kickers (@KRASKickers)
At @ASCO #GI26 we presented our KRAS KICKERS Trial Finder. Personalized: KRAS G12D, CRC, US trials Results (in 4 minutes): 20 trials go to KRASHUB.ORG in beta - would love your feedback abstract asco.org/abstracts-presentat… FYI: G12V - 8 trials for CRC G12R - 7 trials for CRC
3
3
1
10
4,233
A great debate! Dr Paul Oberstein & Dr Ignacio Garrido-Laguna offered different perspectives on whether all patients with PDAC should receive a KRAS inhibitor first #PancreaticCancer @md_oberstein @Aiims1742 @Perlmutter_CC #GICancerSummit2026
1
6
491
KRAS Kickers retweeted
ALTA3263:
2
5
10
609
KRAS Kickers retweeted
Dr. Nilo Azad of @hopkinskimmel discusses “ Continuing the Exploration of Immunotherapy in PDAC in a Post – RAS world. As part of the RAS Story: Biology, Translational Data, and Therapeutics in GI Oncology session during the #RueschSymposium.
1
2
88
Replying to @RueschCenter
@RueschCenter conference today. Dr. Daniel Shu - Current translational data on RAS therapeutics
1
1
2
140
conclusion slide at the #RueschSymposium intriguiing!
49
KRAS Kickers retweeted
Dr. Amrita Cheema of @LombardiCancer discusses “The Biology and Targeting of RAS in GI Cancers” as part of the RAS Story: Biology, Translational Data, and Therapeutics in GI oncology session during the #RueschSymposium.
1
1
90
Another citing of @papkephd - Ras Inhibitors map by Dr. Arthur Winer at the @RueschCenter symposium today. "A continuously updated map of every RAS inhibitor & degrader in clinical development — 75 drugs, from Phase 1 to FDA approval. The entire clinical RAS pipeline at a glance, updated regularly. " rasinhibitors.com
6
12
886
KRAS Kickers retweeted
Dr. Arthur Winer of @InovaSchar discusses “RAS Inhibitors: We’ve Only Just Begun” as part of the RAS Story: Biology, Translational Data, and Therapeutics in GI Oncology session during the #RueschSymposium.
1
3
131
KRAS Kickers retweeted
Join us on November 20, 2026, for a dynamic discussion with Drs. Nilo Azad, Amrita Cheema, Daniel Shu and Arthur Winer. RAS Story: Biology, Translational Data and Therapeutics in GI Oncology. bit.ly/Ruesch26. Use promo code Guest26 to register today. @LombardiCancer @InovaSchar @hopkinskimmel @UMmedschool @OncLive
4
7
332
KRAS Kickers retweeted
Meet the chairs of the Ruesch Center Symposium: John L. Marshall, MD @marshalj23 @LombardiCancer, Nilo S. Azad, MD @HopkinsMedicine, Timothy L. Cannon, MD @InovaHealth, and Petr F. Hausner, MD @UMmedschool. Register: hubs.li/Q04wz78Q0 @MedStarGUH @RueschCenter #GIOnc #RueschCenterSymposium
3
1
5
1,068
On #WorldPancreaticCancerDay, we’re focusing on the progress that is changing what may be possible for patients. KRAS drives the vast majority of pancreatic cancers and, for decades, was considered “undruggable.” That has changed. The challenge now is understanding how tumors respond to KRAS-targeted treatment, how resistance develops, and how to build on those responses to make them deeper and more durable. We left this week’s Break Through Cancer Summit especially energized by the updates from our pancreatic cancer teams: from learning directly from patients through repeated biopsies, to rebuilding tumors in 3D and exploring vaccines designed to help the immune system recognize mutant KRAS. There is still enormous work ahead. But seeing these teams share what they are learning was a powerful reminder of the momentum in the field. #RadicalCollaboration
5
5
527
PANCREATIC CANCER AWARENESS: November 19th 2026 is Pancreatic Cancer Awareness Day. As a survivor myself (6 years since competing chemo), I'm acutely aware of (and reminded daily) the need for early detection. @PanCAN @letswinpc @lustgartenfdn @UCSFCancer
2
10
18
566
ERAS-0015 - bilary cancer data at #ENASymp26 #BTC
7
9
743
KRAS Kickers retweeted
QTX3034:
1
3
3
498
KRAS Kickers retweeted
ERAS-0015:
1
6
1
9
6,824
KRAS Kickers retweeted
Full room for the proffered papers session on “Advances in Targeting RAS” Data on OMO-103, ARV-806, ERAS-0015, PT0253, ALTA3263, Daraxonrasib + GnP, and QTX3034!! #ENASymp26
6
13
1
37
4,491
KRAS Kickers retweeted
Tomorrow more mature phase 1/2 data of $RVMD's daraxonrasib in combination with GnP in 1L metastatic pancreatic cancer (mPDAC) is planned to be presented at ENA 2026 in Barcelona. The AACR update in April reported that 84% of patients were progression free at 6m (n=40, median follow-up 9.7m, median PFS not mature). So what to expect for PFS at 12m? As far as I know there is no other clinical data available for daraxonrasib + GnP in mPDAC. We do not know the shape of the survival curve on this combination therapy. We could look at the PFS curve of GnP monotherapy in 1L mPDAC from the control group of the NAPOLI 3 trial and at the PFS data of daraxonrasib monotherapy from the 2L phase 1/2 cohort. However, this comparison is probably of low informative value as we do not know how resistance to daraxonrasib develops in combination with GnP and how long the combination is tolerable. GnP monotherapy in 1L mPDAC (NAPOLI 3): 6m PFS 43.2%, 12m PFS 13.9%, 18m PFS 3.6% (no plateau, patients progressed about a third faster between 6m and 12m than in the first 6m) Daraxonrasib monotherapy in 2L mPDAC (phase 1/2, 300 mg, n=38): 6m PFS 66%, 9m PFS 38%, median PFS 8.1m (patients progressed about 2.7 times as fast between 6m and 9m as in the first 6m) Let's just assume that patients on daraxonrasib + GnP also progressed about a third faster after 6m than in their first 6m as it was reported on GnP monotherapy. Based on the 6m data we have, this would imply that roughly two thirds of the patients on daraxonrasib + GnP could be still progression free at 12m. The median PFS would then be around 18m to 19m. Given the 95% confidence interval around the 84% at 6m (68% to 93%), the 12m PFS would range from roughly 40% to 85% and the median PFS from roughly 10m to not reached. However, a median PFS of 18m to 19m in mPDAC sounds highly unrealistic to me. In the 2L phase 1/2 cohort on daraxonrasib monotherapy, progression sped up more than on GnP monotherapy. With the same speed-up after 6m, roughly 53% of the patients on daraxonrasib + GnP would still be progression free at 12m. The median PFS would then be around 12m to 13m. Given the 95% confidence interval from the 6m data we have, the 12m PFS would range from roughly 25% to 75% and the median PFS from roughly 8m to not reached. Disclosure: I am long $RVMD. This is not financial advice. I cannot guarantee that the numbers and estimates in this post are correct. Do your own research.
1
5
1
24
3,767
PDAC is the third leading cause of cancer-related deaths in the U.S. Learn the signs and symptoms: pancan.org/facing-pancreatic…
5
14
674
Changes in the trial 554 pts to 623 pts 14 arms to 12 arms MANY changes to the arms clinicaltrials.gov/study/NCT…
Trial opened in 2023 - 49 locations worldwide many expansions in the last year: US, Australia, Denmark, Hong Kong, France, Japan, the UK, Spain. A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies Preclinical research - 2022 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics NCT05786924 clinicaltrials.gov/study/NCT…
2
1
504
expansion to Belgium and Ann Arbor, MI
TARGET-D 201 expansion to Spain and France (already in US & Australia) A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy & W/ Cetuximab, in Patients W/ Metastatic KRAS G12D-Mutated Pancreatic Cancer Opened June 26 180 ps NCT07644559 VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors - Oct 15 cancernetwork.com/view/vs-73… Trial post and links facebook.com/permalink.php?s…
2
3
374